Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P05109 (S100A8)
 1,212 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Oncomodulin is a 108-residue, oncodevelopmental protein containing two calcium-binding sites identified as the CD- and EF-loops. The protein contains no tryptophan and only two tyrosine residues, one which is a calcium ligand in the CD-loop (Tyr-57) and one which lies in the flanking D-helix of this loop (Tyr-65). Site-specific mutagenesis was performed to yield five mutants, two with phenylalanine substituted for tyrosine in positions 57 and 65 and three with tryptophan substituted into position 57 in the CD-loop, position 65 in the D-helix, and position 96 in the EF-loop. The single Tyr-containing mutants demonstrated that position 57 was perturbed to a significantly greater extent than position 65 upon calcium binding. Although both tyrosine residues responded to decalcification, the fluorescence intensity changes were in opposite directions, with the more dominant Tyr-57 accounting for the majority of the intrinsic fluorescence observed in native oncomodulin. The substitution of tryptophan for each tyrosyl residue revealed that in both positions the tryptophan resided in polar, conformationally heterogeneous environments. The environment of Trp-57 was affected by Ca2+ binding to a much greater extent compared to that of Trp-65. Only 1 equiv of Ca2+ was required to produce greater than 70% of the Trp fluorescence changes in positions 57 and 65, indicating that Ca2+ binding to the higher affinity EF-loop had a pronounced effect on the protein structure.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Metal-induced changes in the fluorescence properties of tyrosine and tryptophan site-specific mutants of oncomodulin. 185 60

Oncomodulin (ONCO) is an oncodevelopmental protein expressed in placental and extraembryonic tissue and re-expressed in a wide variety of tumors. The metallothionein promoter (MT) is active in numerous adult tissues, in parietal and visceral extraembryonic endoderm, and developing liver. To study the function of oncomodulin we microinjected MT-ONCO DNA into one-cell embryos and examined tissues of fetal and adult mice. Analysis of implant sites from embryos, microinjected with MT-ONCO DNA then placed into pseudopregnant females, indicated a greater than three-fold increase in empty and necrotic implant sites relative to SV2NEO-microinjected embryos and a seven-fold rise relative to non-microinjected embryos. The striking feature of the lethality was the presence of a normal placenta but absence of fetal tissue. Few MT-ONCO DNA transgenic mice were isolated (3.5%) and none were able to express oncomodulin protein or RNA in any tissue examined, even after prolonged heavy metal stimulation of the MT promoter. Fetal mortality is best correlated with expression of oncomodulin causing an interruption of either cellular differentiation or organogenesis before day 9 in development.
 ...
PMID:Microinjection of metallothionein-oncomodulin DNA into fertilized mouse embryos is correlated with fetal lethality. 247 84

The calcium-binding protein oncomodulin, previously found only in tumors, has been detected during rat development. Specific antisera to purified rat hepatoma oncomodulin (MW 11,500) were used to detect oncomodulin by radioimmunoassay (RIA) and by avidin-biotin-peroxidase complex (ABC) immunohistochemistry. Using RIA, oncomodulin was found to increase in placenta from below the limits of detection (2 ng/mg protein) on Day 13 to approximately 25 ng/mg on Day 16 of pregnancy, and to remain high through to the end of gestation. Determinations on separated inner and outer placenta showed the increase to be greater in the outer placenta (basal zone and decidua) than in the inner placenta (labyrinth). The ABC technique on paraffin sections produced positive staining for oncomodulin throughout the placenta, with the most intense staining occurring in the outer placenta (cytotrophoblast and giant cells of the basal zone). Parietal and visceral yolk sac, and amnion also stained positively, while fetal organs did not. Oncomodulin synthesis measured by [35S]methionine incorporation into immunoprecipitates occurred in isolated inner and outer placenta, whole placenta, the separated trophectoderm and endoderm of the parietal yolk sac, and amnion. No oncomodulin synthesis could be measured in visceral yolk sac, fetal liver, or 16-day embryo. This occurrence in developing and transformed tissues demonstrates that oncomodulin is an oncodevelopmental protein.
 ...
PMID:Localization and synthesis of the tumor protein oncomodulin in extraembryonic tissues of the fetal rat. 390 38

Oncomodulin, first found in tumours, turns out to be a highly conserved oncodevelopmental protein in human and rodent placentas. The human and rat placental oncomodulins were visualised immunohistochemically. The placental oncomodulins are identical to each other, and to tumour oncomodulin with respect to amino acid composition, chromatographic elution and the pattern of the peptides released by trypsin action.
 ...
PMID:The widely-distributed tumour protein, oncomodulin, is a normal constituent of human and rodent placentas. 400 27